Desensitization of the soluble guanylyl cyclase/cGMP pathway by lipopolysaccharide in rat isolated pulmonary artery but not aorta

British Journal of Pharmacology

Volumn 155, Issue 8, 2008, Pages 1164-1173

  El Awady, M S H ^a   Smirnov, S V ^a   Watson, M L ^a  

^a University of Bath   (United Kingdom)

Author keywords

Aorta; cGMP; ET 1; LPS; NO; PDE5; Pulmonary artery; SGC

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; CYCLIC GMP; GUANYLATE CYCLASE; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE V INHIBITOR; T 0156; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AORTA; ARTERY CONSTRICTION; ARTERY DILATATION; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DESENSITIZATION; ENDOTHELIUM; ISOLATED ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; RAT;

ANIMALS; AORTA; CYCLIC GMP; ENZYME ACTIVATION; GUANYLATE CYCLASE; LIPOPOLYSACCHARIDES; MALE; MUSCLE CONTRACTION; NITRIC OXIDE; NITROPRUSSIDE; PULMONARY ARTERY; RATS; RATS, WISTAR;

EID: 57349099556     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.358     Document Type: Article

References (40)

1. Alexander SP, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl 2): S1-S209.
2. Bachetti T, Pasini E, Suzuki H, Ferrari R (2003). Species-specific modulation of the nitric oxide pathway after acute experimentally induced endotoxemia. Crit Care Med 31: 1509-1514.
3. Bishop-Bailey D, Larkin SW, Warner TD, Chen G, Mitchell JA (1997). Characterization of the induction of nitric oxide synthase and cyclo-oxygenase in rat aorta in organ culture. Br J Pharmacol 121: 125-133.
4. Boerrigter G, Burnett Jr JC (2007). Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. Cardiovasc Drug Rev 25: 30-45.
5. +-ATPase in the aorta from rats with endotoxic shock. Shock 23: 179-185.
6. Curzen NP, Kaddoura S, Griffiths MJ, Evans TW (1997). Endothelin-1 in rat endotoxemia: mRNA expression and vasoreactivity in pulmonary and systemic circulations. Am J Physiol 272: H2353-H2360.
7. Cuzzocrea S, Mazzon E, Di PR, Esposito E, Macarthur H, Matuschak GM et al. (2006). A role for nitric oxide-mediated peroxynitrite formation in a model of endotoxin-induced shock. J Pharmacol Exp Ther 319: 73-81.
8. Feihl F, Waeber B, Liaudet L (2001). Is nitric oxide overproduction the target of choice for the management of septic shock? Pharmacol Ther 91: 179-213.
9. Fernandes D, da Silva-Santos JE, Duma D, Villela CG, Barja-Fidalgo C, Assreuy J (2006). Nitric oxide-dependent reduction in soluble guanylate cyclase functionality accounts for early lipopolysaccharide-induced changes in vascular reactivity. Mol Pharmacol 69: 983-990.
10. Friebe A, Koesling D (2003). Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 93: 96-105.
11. Fujii Y, Magder S, Cernacek P, Goldberg P, Guo Y, Hussain SN (2000). Endothelin receptor blockade attenuates lipopolysaccharide-induced pulmonary nitric oxide production. Am J Respir Crit Care Med 161: 982-989.
12. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B (1995). Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol 48: 184-188.
13. Garvey EP, Oplinger JA, Furfine ES, Kiff RJ, Laszlo F, Whittle BJ et al. (1997). 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J Biol Chem 272: 4959-4963.
14. Glynos C, Kotanidou A, Orfanos SE, Zhou Z, Simoes DC, Magkou C et al. (2007). Soluble guanylyl cyclase expression is reduced in LPS-induced lung injury. Am J Physiol Regul Integr Comp Physiol 292: R1448-R1455.
15. Griffiths MJ, Liu S, Curzen NP, Messent M, Evans TW (1995). In vivo treatment with endotoxin induces nitric oxide synthase in rat main pulmonary artery. Am J Physiol 268: L509-L518.
16. Holzmann A, Bloch KD, Sanchez LS, Filippov G, Zapol WM (1996). Hyporesponsiveness to inhaled nitric oxide in isolated, perfused lungs from endotoxin-challenged rats. Am J Physiol 271: L981-L986.
17. Juilfs DM, Soderling S, Burns F, Beavo JA (1999). Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs). Rev Physiol Biochem Pharmacol 135: 67-104.
18. Knotek M, Esson M, Gengaro P, Edelstein CL, Schrier RW (2000). Desensitization of soluble guanylate cyclase in renal cortex during endotoxemia in mice. J Am Soc Nephrol 11: 2133-2137.
19. Kuklin VN, Kirov MY, Evgenov OV, Sovershaev MA, Sjoberg J, Kirova SS et al. (2004). Novel endothelin receptor antagonist attenuates endotoxin-induced lung injury in sheep. Crit Care Med 32: 766-773.
20. Lin CS, Lin G, Xin ZC, Lue TF (2006). Expression, distribution and regulation of phosphodiesterase 5. Curr Pharm Des 12: 3439-3457.
21. Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S et al. (2004). Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 32: 21-30.
22. Lorente JA, Landin L, Renes E, De PR, Jorge P, Rodena E et al. (1993). Role of nitric oxide in the hemodynamic changes of sepsis. Crit Care Med 21: 759-767.
23. Manthous CA, Hall JB, Samsel RW (1993). Endotoxin in human disease. Part 2: biologic effects and clinical evaluations of antiendotoxin therapies. Chest 104: 1872-1881.
24. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR et al. (2003). Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 64: 533-546.
25. McIntyre Jr RC, Sheridan B, Agrafojo J, Fullerton DA (1997). Endotoxin differentially impairs cyclic guanosine monophosphate-mediated relaxation in the pulmonary and systemic circulations. Crit Care Med 25: 318-323.
26. McKenna TM (1990). Prolonged exposure of rat aorta to low levels of endotoxin in vitro results in impaired contractility. Association with vascular cytokine release. J Clin Invest 86: 160-168.
27. Mochida H, Takagi M, Inoue H, Noto T, Yano K, Fujishige K et al. (2002). Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor. Eur J Pharmacol 456: 91-98.
28. O'Brien AJ, Wilson AJ, Sibbald R, Singer M, Clapp LH (2001). Temporal variation in endotoxin-induced vascular hyporeactivity in a rat mesenteric artery organ culture model. Br J Pharmacol 133: 351-360.
29. Papapetropoulos A, Abou-Mohamed G, Marczin N, Murad F, Caldwell RW, Catravas JD (1996). Downregulation of nitrovasodilator-induced cyclic GMP accumulation in cells exposed to endotoxin or interleukin-1 beta. Br J Pharmacol 118: 1359-1366.
30. Parsons PE, Worthen GS, Moore EE, Tate RM, Henson PM (1989). The association of circulating endotoxin with the development of the adult respiratory distress syndrome. Am Rev Respir Dis 140: 294-301.
31. Piechota M, Banach M, Irzmanski R, Barylski M, Piechota-Urbanska M, Kowalski J et al. (2007). Plasma endothelin-1 levels in septic patients. J Intensive Care Med 22: 232-239.
32. Pittet JF, Morel DR, Hemsen A, Gunning K, Lacroix JS, Suter PM et al. (1991). Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis. Ann Surg 213: 261-264.
33. Scott WS, Nakayama DK (1998). Escherichia coli lipopolysaccharide downregulates soluble guanylate cyclase in pulmonary artery smooth muscle. J Surg Res 80: 309-314.
34. Stasch JP, Becker EM, onso-Alija C, Apeler H, Dembowsky K, Feurer A et al. (2001). NO-independent regulatory site on soluble guanylate cyclase. Nature 410: 212-215.
35. Szabo C, Salzman AL, Ischiropoulos H (1995). Endotoxin triggers the expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in the rat aorta in vivo. FEBS Lett 363: 235-238.
36. Takata M, Filippov G, Liu H, Ichinose F, Janssens S, Bloch DB et al. (2001). Cytokines decrease sGC in pulmonary artery smooth muscle cells via NO-dependent and NO-independent mechanisms. Am J Physiol Lung Cell Mol Physiol 280: L272-L278.
37. Toward TJ, Nials AT, Johnson FJ (2005). Guinea-pig lung adenylyl and guanylyl cyclase and PDE activities associated with airway hyper- and hypo-reactivity following LPS inhalation. Life Sci 76: 997-1011.
38. Wanecek M, Oldner A, Rudehill A, Sollevi A, Alving K, Weitzberg E (1999). Endothelin(A)-receptor antagonism attenuates pulmonary hypertension in porcine endotoxin shock. Eur Respir J 13: 145-151.
39. Wu CC, Chen SJ, Yen MH (1998). Nitric oxide-independent activation of soluble guanylyl cyclase contributes to endotoxin shock in rats. Am J Physiol 275: H1148-H1157.
40. Zingarelli B, Hasko G, Salzman AL, Szabo C (1999). Effects of a novel guanylyl cyclase inhibitor on the vascular actions of nitric oxide and peroxynitrite in immunostimulated smooth muscle cells and in endotoxic shock. Crit Care Med 27: 1701-1707.